| Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology I Vanmeerbeek, J Sprooten, D De Ruysscher, S Tejpar, P Vandenberghe, ... Oncoimmunology 9 (1), 1703449, 2020 | 191 | 2020 |
| Necroptosis in immuno-oncology and cancer immunotherapy J Sprooten, P De Wijngaert, I Vanmeerbeek, S Martin, P Vangheluwe, ... Cells 9 (8), 1823, 2020 | 113 | 2020 |
| Trial watch: Dendritic cell (DC)-based immunotherapy for cancer RS Laureano, J Sprooten, I Vanmeerbeerk, DM Borras, J Govaerts, ... Oncoimmunology 11 (1), 2096363, 2022 | 65 | 2022 |
| Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer J Sprooten, A Vankerckhoven, I Vanmeerbeek, DM Borras, Y Berckmans, ... Journal for Immunotherapy of Cancer 9 (11), 2021 | 28 | 2021 |
| Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy I Vanmeerbeek, DM Borras, J Sprooten, O Bechter, S Tejpar, AD Garg Genes & Immunity 22 (2), 108-119, 2021 | 20 | 2021 |
| Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer S Naulaerts, A Datsi, DM Borras, A Antoranz Martinez, J Messiaen, ... Science Translational Medicine 15 (691), eadd1016, 2023 | 18 | 2023 |
| Trial watch: chemotherapy-induced immunogenic cell death in oncology J Sprooten, RS Laureano, I Vanmeerbeek, J Govaerts, S Naulaerts, ... Oncoimmunology 12 (1), 2219591, 2023 | 17 | 2023 |
| Efficacy of CD40 agonists is mediated by distinct cDC subsets and subverted by suppressive macrophages A Murgaski, M Kiss, H Van Damme, D Kancheva, I Vanmeerbeek, ... Cancer Research 82 (20), 3785-3801, 2022 | 13 | 2022 |
| The interface of tumour-associated macrophages with dying cancer cells in immuno-oncology I Vanmeerbeek, J Govaerts, RS Laureano, J Sprooten, S Naulaerts, ... Cells 11 (23), 3890, 2022 | 11 | 2022 |
| Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer DM Borràs, S Verbandt, M Ausserhofer, G Sturm, J Lim, GA Verge, ... Cell Discovery 9 (1), 114, 2023 | 9 | 2023 |
| Immunogenomic, single-cell and spatial dissection of CD8+T cell exhaustion reveals critical determinants of cancer immunotherapy S Naulaerts, DM Borras, AA Martinez, J Messiaen, Y Van Herck, L Gelens, ... BioRxiv, 2021.11. 22.468617, 2021 | 7 | 2021 |
| Necroptosis in Immuno-Oncology and Cancer Immunotherapy. Cells. 2020; 9: 1823 J Sprooten, P De Wijngaert, I Vanmeerbeerk, S Martin, P Vangheluwe, ... | 5 | |
| A lymph node-to-tumour PDL1+macrophage circuit antagonizes dendritic cell immunotherapy J Sprooten, I Vanmeerbeek, A Datsi, J Govaerts, DM Borràs, S Naulaerts, ... bioRxiv, 2023.03. 14.532534, 2023 | 2 | 2023 |
| Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells J Sprooten, I Vanmeerbeek, A Datsi, J Govaerts, S Naulaerts, ... Cell Reports Medicine 5 (1), 2024 | 1 | 2024 |
| The cell stress and immunity cycle in cancer: Toward next generation of cancer immunotherapy RS Laureano, I Vanmeerbeek, J Sprooten, J Govaerts, S Naulaerts, ... Immunological Reviews 321 (1), 71-93, 2024 | 1 | 2024 |
| Reverse translation: the key to increasing the clinical success of immunotherapy? I Vanmeerbeek, S Naulaerts, AD Garg Genes & Immunity 24 (5), 217-219, 2023 | 1 | 2023 |
| 894 Conserved immune inhibitory receptor-signaling in macrophages limits antitumour chemo-immunotherapy I Vanmeerbeek, S Naulaerts, J Sprooten, R Salvador, J Govaerts, R Trotta, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 1907P Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB) L Kinget, S Naulaerts, J Govaerts, I Vanmeerbeek, J Sprooten, ... Annals of Oncology 34, S1026-S1027, 2023 | | 2023 |
| Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy (vol 22, pg 108, 2021) I Vanmeerbeek, DM Borras, J Sprooten, O Bechter, S Tejpar, AD Garg Genes And Immunity 23 (8), 260-260, 2022 | | 2022 |
| Publisher Correction: Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy I Vanmeerbeek, DM Borras, J Sprooten, O Bechter, S Tejpar, AD Garg Genes & Immunity 23 (8), 260-260, 2022 | | 2022 |
